Ibrutinib is a Bruton's tyrosine kinase inhibitor which interferes with signaling through the B-cell receptor pathway. Ibrutinib is metabolized via cytochrome P450 enzyme 3A. Potential drug interactions need to be considered with its use. Ibrutinib is generally well tolerated. Diarrhea and skin rashes are relatively common, often transient, and can resolve with no specific management. Bleeding, atrial fibrillation, arthritis and arthralgia, fatigue, cytopenias, and infections are more serious but less common drug specific complications.